骨硬化蛋白单克隆抗体单用与联合黄芪对去卵巢诱导的骨质疏松疗效比较

目的：探讨骨硬化蛋白单克隆抗体（Scl-Ab）单用与联合黄芪对去卵巢诱导的骨质疏松治疗效果的比较。方法：随机将30只雌性健康SD大鼠行切除双侧卵巢手术（OVX组，n=25）和假手术（Sham组，n=5），手术12周后各取5只大鼠处死并取股骨行Micro-CT检测骨质疏松动物模型是否建立。建模成功后将OVX组大鼠随机分成2组：Scl-Ab组和Scl-Ab+黄芪组。术后第1天Scl-Ab+黄芪组给予药物治疗：Scl-Ab皮下注射（12.5 mg/kg，每周2次）；同时每天给于200 mg/kg黄芪液灌胃，直至12周。Scl-Ab组则给予Scl-Ab皮下注射（25 mg/kg，每周2次），并且每天给予200 mg/kg 0.9%氯化钠溶液灌胃，直至12周。用药12周时处死所有大鼠并取股骨行Micro-CT、硬组织切片检测。结果：与Scl-Ab组比，Scl-Ab+黄芪组大鼠股骨远端有较高的股骨BMD、BV/TV、Tb.Th、Tb.N、Conn.D、MAR和较低的Tb.Sp，差异有统计学意义（P＜0.05）。结论：Scl-Ab联合黄芪对去卵巢诱导的大鼠骨质疏松治疗效果要优于单用Scl-Ab。

The effect of sclerostin-antibody or sclerostin-antibody with Astragalus membranaceus on ovariectomized osteoporosis: a comparative study

Objective: To compare the therapeutic effect of Sclerostin-antibody and Sclerostin-antibody with Astragalus membranaceus on osteoporosis in OVX rats. Methods: Bilateral ovariectomy (OVX, n=25) and sham (Sham, n=5) operation were performed in 30 healthy female SD rats at random. After 12 weeks, 5 rats in each group were executed and their femurs were taken for micro-CT to detect whether the osteoporosis animal model was established. When the model of osteoporosis is established successfully, all animals from OVX (n=20) group randomly divided into two groups:group Scl-Ab+Astragalus membranaceus and group Scl-Ab. Then group Scl-Ab+Astragalus membranaceus was given Scl-Ab (12.5 mg/kg, two times a week) by hypodermic injection and Astragalus membranaceus extract [200 mg/(kg·d), once a day] by gavage, Scl-Ab group was given Scl-Ab (25 mg/kg, two times a week) by hypodermic injection and saline [200 mg/(kg·d), once a day] by gavage. The femurs of rats were harvested for evaluation. The results of treatment for osteoporosis were evaluated by micro-computerized tomography and undecalcified sliced. Results: Compared with group Scl-Ab, the distal femurs from group Scl-Ab+astragalus membranaceus have a higher BMD, BV/TV, Tb.Th, Tb.N, Conn. D bone mineral apposition rates and a lower Tb.Sp. Conclusion: The results of this study indicates that Sclerostin-antibody with Astragalus membranaceus is superior to Sclerostin-antibody only in the treatment of ovariectomized osteoporosis in rats.